Cancerous disease modifying antibodies
OwnerDavid S. F. Young, Susan E. Hahn +1inventors
InventorsDavid S. F. Young, Susan E. Hahn, Helen P. Findlay
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
Claims8
The isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690.
The isolated hybridoma deposited with the ATCC as Accession Number PTA-5690.
A binding assay to determine presence of cancerous cells in a tissue sample selected from a human colon tumor comprising:
- providing a tissue sample from said human colon tumor;
- providing an isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690 or antigen binding fragment thereof;
- or an antibody conjugate thereof;
- contacting said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;
- and
- determining binding of said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;
- whereby the presence of said cancerous cells in said tissue sample is indicated.
A process of isolating or screening for cancerous cells in a tissue sample selected from a human colon tumor comprising:
- providing a tissue sample from said human colon tumor;
- providing an isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as Accession Number PTA-5690 or antigen binding fragment thereof;
- or an antibody conjugate thereof;
- contacting said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;
- and
- determining binding of said isolated monoclonal antibody or antigen binding fragment thereof or antibody conjugate thereof with said tissue sample;
- whereby said cancerous cells are isolated by said binding and their presence in said tissue sample is confirmed.
Dependencies are inferred from the claim text.